Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society

@article{Carpenter2015NonhormonalMO,
  title={Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society},
  author={Janet S. Carpenter and Margery L. S. Gass and Pauline M. Maki and Katherine M. Newton and JoAnn V. Pinkerton and Maida B Taylor and Wulf. H. Utian and P F Schnatz and Andrew M. Kaunitz and Marla Shapiro and Jan L. Shifren and Howard N. Hodis and Sheryl A Kingsberg and James H. Liu and Gloria A. Richard-Davis and Nanette F Santoro and Lynnette Leidy Sievert and Isaac Schiff and Caitlin A. Pike},
  journal={Menopause},
  year={2015},
  volume={22},
  pages={1155–1174}
}
Objective:To update and expand The North American Menopause Society's evidence-based position on nonhormonal management of menopause-associated vasomotor symptoms (VMS), previously a portion of the position statement on the management of VMS. Methods:NAMS enlisted clinical and research experts in the field and a reference librarian to identify and review available evidence. Five different electronic search engines were used to cull relevant literature. Using the literature, experts created a… Expand
Nonpharmacologic, nonherbal management of menopause-associated vasomotor symptoms: an umbrella systematic review (protocol)
TLDR
An umbrella review, supplemented by an additional search for eligible RCTs, aims to synthesize existing evidence on the use of nonpharmacologic, nonherbal interventions to manage bothersome vasomotor symptoms in perimenopausal and postmenopausal women. Expand
Challenges in the Treatment of Vasomotor Symptoms: Update in Non-Hormonal Strategies
TLDR
The literature review shows that serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptakes inhibitors (SSRIs%), antihypertensives and anticonvulsants, decrease the intensity and frequency of VMS, proving a clinically significant improvement. Expand
Fezolinetant in the treatment of vasomotor symptoms associated with menopause
TLDR
Fezolinetant is the most advanced NK3R antagonist in clinical development for menopause-associated VMS, and results to date have demonstrated rapid and substantial reduction in VMS frequency and severity and associated improvements in health-related quality of life. Expand
Consensus statement for non-hormonal based treatments for menopausal symptoms
  • J. Woyka
  • Medicine
  • Post reproductive health
  • 2020
TLDR
Recommendations from NICE 2015 guidelines and other international bodies are incorporated, and much of the most recent information comes from studies involving breast cancer survivors. Expand
An eHealth approach to treating vasomotor symptoms.
TLDR
Both group CBT and self-guided CBT are effective in treating VMS, and CBT significantly reduced VMS problem ratings at 9 weeks after randomization compared with usual care, and improvements were maintained at 26 weeks. Expand
Making choices at menopause.
TLDR
The aim of this article is to review the key components of the assessment of women who are perimenopausal or menopausal, and to discuss the benefits and risks of hormonal and non-hormonal treatments, thereby assisting clinicians to appropriately manage these women. Expand
Nocturia through the menopausal transition and beyond: a narrative review
TLDR
The aim of this review was to synthesize the current evidence regarding the incidence, impact, pathophysiology, and specific diagnostic approach of nocturia in the postmenopausal population. Expand
Alternatives to hormone therapy for management of climacteric syndrome
TLDR
Information accumulated to date on the efficacy and safety of phytoestrogens (red clover extract) makes it possible to recommend them as an alternative to MHT for the treatment of disorders associated with involutive changes in the female reproductive system during the peri- and postmenopausal period. Expand
Bazedoxifene and Conjugated Equine Estrogen: A Combination Product for the Management of Vasomotor Symptoms and Osteoporosis Prevention Associated with Menopause
TLDR
Although this TSEC manages VMS while opposing breast and endometrial proliferation, preventing bone resorption, and improving lipid profiles, long‐term experience with BZA/CE is currently lacking. Expand
Hormone Therapy in Menopause.
  • John Paciuc
  • Medicine
  • Advances in experimental medicine and biology
  • 2020
TLDR
The compelling argument from notable thought-leaders that estrogen, in those without contraindications, should be considered for primary prevention of cardiovascular disease as well as the prevention of chronic disease is reviewed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 213 REFERENCES
Relaxation for perimenopausal and postmenopausal symptoms.
TLDR
Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration. Expand
Exercise for vasomotor menopausal symptoms.
TLDR
No evidence is found from randomised controlled trials on whether exercise is an effective treatment relative to other interventions or no intervention in reducing hot flushes and or night sweats in symptomatic women. Expand
Therapeutic decisions for menopause: results of the DAMES project in central Massachusetts
TLDR
This study documents a relatively heavy burden of symptoms in a relatively healthy population and provides an update on earlier studies in Massachusetts. Expand
Chiropractic intervention in the treatment of postmenopausal climacteric symptoms and insomnia: A review.
TLDR
A lack of evidence for chiropractic intervention as a complementary and alternative therapeutic method in the management of menopausal symptoms and insomnia is demonstrated. Expand
S-equol: a potential nonhormonal agent for menopause-related symptom relief.
TLDR
The preliminary evidence warrants clinicians discussing the potential of S-equol for the alleviation of VMS with patients, and subanalysis of epidemiologic studies suggests that equol producers are more likely to benefit from soyfood consumption than nonproducers with respect to both cardiovascular disease and osteoporosis, although the data are inconsistent. Expand
A pilot observational study to assess the safety and efficacy of Menoprogen for the management of menopausal symptoms in Chinese women.
TLDR
The present pilot study found that Menoprogen reduced symptoms associated with perimenopausal and postmenopausal complaints, and the rationale for a randomized, placebo-controlled clinical trial is supported. Expand
Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review.
TLDR
Although individual trials suggest benefits from certain therapies, data are insufficient to support the effectiveness of any complementary and alternative therapy in this review for the management of menopausal symptoms. Expand
Use of complementary and alternative medicine during the menopause transition: longitudinal results from the Study of Women's Health Across the Nation
TLDR
Although CAM use did vary in some ethnic groups in relation to advancing menopause status, there was no evidence of influence of calendar time on CAM use. Expand
Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis.
TLDR
The SSRIs or SNRIs, clonidine, and gabapentin trials provide evidence for efficacy; however, effects are less than for estrogen, few trials have been published and most have methodological deficiencies, generalizability is limited, and adverse effects and cost may restrict use for many women. Expand
Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.
TLDR
Low-dose oral estradiol and venlafaxine are effective treatments for VMS in women during midlife and the difference in efficacy and tolerability is small and of uncertain clinical relevance. Expand
...
1
2
3
4
5
...